BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $384,788 | -49.5% | 10,196 | -39.0% | 0.01% | -47.4% |
| Q2 2023 | $761,934 | +17.3% | 16,724 | +4.4% | 0.02% | +5.6% |
| Q1 2023 | $649,761 | +116.7% | 16,020 | +172.3% | 0.02% | +100.0% |
| Q4 2022 | $299,895 | -28.6% | 5,884 | -24.5% | 0.01% | -35.7% |
| Q3 2022 | $420,000 | -9.3% | 7,791 | +8.1% | 0.01% | -12.5% |
| Q2 2022 | $463,000 | -17.3% | 7,205 | -0.2% | 0.02% | -5.9% |
| Q1 2022 | $560,000 | -13.6% | 7,221 | -4.3% | 0.02% | -15.0% |
| Q4 2021 | $648,000 | +7.3% | 7,549 | +0.5% | 0.02% | -4.8% |
| Q3 2021 | $604,000 | +2.2% | 7,512 | +2.2% | 0.02% | -12.5% |
| Q2 2021 | $591,000 | -5.3% | 7,348 | -0.6% | 0.02% | -14.3% |
| Q1 2021 | $624,000 | +5.1% | 7,394 | -0.2% | 0.03% | 0.0% |
| Q4 2020 | $594,000 | -6.8% | 7,409 | -6.4% | 0.03% | -17.6% |
| Q3 2020 | $637,000 | -13.9% | 7,915 | -7.9% | 0.03% | -24.4% |
| Q2 2020 | $740,000 | +14.2% | 8,598 | +7.7% | 0.04% | -19.6% |
| Q1 2020 | $648,000 | +18.2% | 7,980 | +21.7% | 0.06% | +40.0% |
| Q4 2019 | $548,000 | -17.8% | 6,556 | -14.0% | 0.04% | -27.3% |
| Q3 2019 | $667,000 | +29.0% | 7,626 | +20.9% | 0.06% | +22.2% |
| Q2 2019 | $517,000 | +2.0% | 6,308 | +1.1% | 0.04% | +4.7% |
| Q1 2019 | $507,000 | +24.9% | 6,238 | +1.2% | 0.04% | +13.2% |
| Q4 2018 | $406,000 | -25.8% | 6,165 | -13.2% | 0.04% | -32.1% |
| Q3 2018 | $547,000 | -9.7% | 7,102 | -13.5% | 0.06% | -17.6% |
| Q2 2018 | $606,000 | +20.2% | 8,206 | +6.0% | 0.07% | +15.3% |
| Q1 2018 | $504,000 | +32.6% | 7,744 | +31.6% | 0.06% | +28.3% |
| Q4 2017 | $380,000 | +35.7% | 5,886 | +31.9% | 0.05% | +24.3% |
| Q3 2017 | $280,000 | +1.1% | 4,461 | -2.5% | 0.04% | -7.5% |
| Q2 2017 | $277,000 | +15.9% | 4,574 | -0.8% | 0.04% | +14.3% |
| Q1 2017 | $239,000 | +191.5% | 4,612 | +169.2% | 0.04% | +191.7% |
| Q3 2016 | $82,000 | +13.9% | 1,713 | +7.2% | 0.01% | +9.1% |
| Q2 2016 | $72,000 | +9.1% | 1,598 | 0.0% | 0.01% | 0.0% |
| Q1 2016 | $66,000 | +26.9% | 1,598 | +17.2% | 0.01% | +10.0% |
| Q4 2015 | $52,000 | +20.9% | 1,363 | +5.3% | 0.01% | 0.0% |
| Q3 2015 | $43,000 | +258.3% | 1,294 | +627.0% | 0.01% | +233.3% |
| Q2 2015 | $12,000 | +140.0% | 178 | +134.2% | 0.00% | +200.0% |
| Q1 2015 | $5,000 | +150.0% | 76 | +123.5% | 0.00% | – |
| Q4 2014 | $2,000 | -91.3% | 34 | -89.4% | 0.00% | -100.0% |
| Q3 2014 | $23,000 | +2200.0% | 320 | +2809.1% | 0.01% | – |
| Q2 2014 | $1,000 | -93.8% | 11 | -95.0% | 0.00% | -100.0% |
| Q1 2014 | $16,000 | -30.4% | 220 | -33.9% | 0.01% | -25.0% |
| Q4 2013 | $23,000 | +2200.0% | 333 | +2927.3% | 0.01% | – |
| Q3 2013 | $1,000 | 0.0% | 11 | 0.0% | 0.00% | -100.0% |
| Q2 2013 | $1,000 | – | 11 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |